Healthy Female Army
No Result
View All Result
  • Healthcare
  • Health and Medicine
  • Health News
  • Staying Healthy
  • Healthcare
  • Health and Medicine
  • Health News
  • Staying Healthy
No Result
View All Result
Healthy Female Army
No Result
View All Result
Home Healthcare

Health Care — Biden push to expand Paxlovid faces obstacles

by
May 2, 2022
in Healthcare
0
Health Care — Biden push to expand Paxlovid faces obstacles
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

AP Photo/Susan Walsh

This “Jeopardy!” contestant singing the alphabet backwards is the video, and hidden talent, you didn’t know you needed to see.  

Today in health care, the White House is pushing to make the highly-effective Pfizer treatment Paxlovid more available, but obstacles remain.  

Welcome to Overnight Health Care, where we’re following the latest moves on policy and news affecting your health. For The Hill, we’re Peter Sullivan, Nathaniel Weixel and Joseph Choi. Someone forward you this newsletter? Subscribe here.

White House’s Paxlovid push hits hurdles

The Biden administration has gone all in on the COVID-19 antiviral Paxlovid, announcing new measures to make the oral treatment more widely available and making it clear that Vice President Harris used it as she recovered from the coronavirus. 

The White House has said it will nearly double the amount of Paxlovid available around the country and that it is working to set up more Test-to-Treat locations in pharmacies and other locations. 

But the administration faces a number of obstacles in really making Paxlovid, and a similar treatment from Merck and Ridgeback known as molnupiravir easily accessible to Americans. 

Health care experts who spoke with The Hill said the expansion plan failed to account for the difficulty that many patients face in actually acquiring a prescriptions for the oral drugs. 

Health care providers who are authorized to prescribe Paxlovid — physicians and advanced practice nurses — are not always staffed at pharmacies.  

Tom Kraus, vice president of government relations at the American Society of Health-System Pharmacists (ASHP), said this situation will be “operationally quite challenging” to the administration’s goal of expanding Test to Treat locations. 

Read more here.

NYC raises COVID-19 alert level to ‘medium’ 

New York City on Monday raised its COVID-19 alert level from “low” to “medium,” amid a rise in cases in the city.   

The move did not trigger any major new restrictions, but it is a sign of the continued risk from the virus and an uptick in cases that has also been seen on a national level.   

If the alert level rises again, to “high,” then the city will consider bringing back its mask mandate for indoor settings, according to New York’s color-coded system.   

“If you are at a higher risk for severe disease due to age, underlying health conditions or because you are unvaccinated, consider additional precautions such as avoiding crowded indoor gatherings,” New York City Health Commissioner Ashwin Vasan tweeted Monday in announcing the move.   

“We continue to strongly recommend all New Yorkers wear a mask in public indoor settings,” he added.  

Cases have ticked up in New York City to around 2,300 per day, according to a New York Times tracker, though there is no sign of a steep spike like there was over the winter.   

Hospitalizations in the city have also ticked up but are still at relatively low levels. 

Read more here.

MODERNA EXPECTS OMICRON BOOSTER AVAILABLE BY FALL

Moderna’s Chief Medical Officer Paul Burton said on Sunday that his company was preparing to provide large amounts of its vaccine booster against omicron and other COVID-19 variants this fall.  

“We’re confident by the fall of this year we should have large amounts of that new booster vaccine that will protect against Omicron and other variants,” Burton said in

an interview on CBS’s “Face the Nation.” 

Last month, Moderna announced that its new bivalent COVID-19 booster shot was more effective against all variants than the company’s currently available coronavirus vaccine. 

The company has said it expects initial data on its omicron-specific vaccine to be available in the second quarter of this year 

Burton also made a general push on Sunday for people who have not already done so to receive their COVID-19 booster. 

“People are eligible now to get boosted. I would absolutely recommend it,” he said on Sunday. 

Read more here.

AMAZON WORKERS LOSE PAID COVID LEAVE

Amazon will no longer offer paid time off for employees with COVID-19. 

The online retail giant announced the change, which went into effect on Monday after the Centers for Disease Control and Prevention changed its guidance surrounding the virus and the widespread availability of vaccines in the U.S. 

Under the new policy, employees who contract COVID-19 will be given five days of excused, unpaid leave, according to a Saturday memo to employees. 

Workers are also still allowed to use their sick time if needed. The memo also noted that Amazon will no longer send site-wide alerts about positive COVID-19 cases, and face coverings are no longer required, though they remain strongly recommended for unvaccinated employees. 

Amazon has been slowly dialing back its COVID-19 leave policies since the start of the year. 

In January, it shortened its paid leave policy for employees from 10 days to seven days. That change was fueled largely by labor shortages caused by the rapid spread of the omicron variant. 

Read more here.

FDA expands approval of non-stimulant ADHD drug

The Food and Drug Administration (FDA) has expanded its approval of a non-stimulant drug for ADHD, the first in about 20 years, to include adults along with children. 

Viloxazine, sold commercially as Qelbree in extended-release capsules, has been approved to help treat ADHD in adults 18 and over, its maker, Supernus Pharmaceuticals, announced. 

Qelbree was first approved for treating children ages 6 to 17 with ADHD last April. At the time, it was the first such drug approved in more than 10 years for children. 

Viloxazine was once prescribed as an antidepressant in Europe before being abandoned in favor of newer drugs. Before last year, it had never been approved for use in the U.S. 

The most common side effects are milder and include decreased appetite, sleepiness and vomiting. 

As a non-stimulant drug, Qelbree is less addictive and less likely to be abused. According to Supernus, no evidence of abuse potential was found during clinical trials. 

Read more here.

WHAT WE’RE READING

US pediatricians’ group moves to abandon race-based guidance (AP 
Mental health shouldn’t be “treated like a stepchild” to physical health, says HHS chief (CBS News) 
Three Children Died of Acute Hepatitis in Indonesia Last Month (Bloomberg)

STATE BY STATE

California Opens Medicaid to Older Unauthorized Immigrants (Kaiser Health News) 
Beto O’Rourke says Texas can learn from Oklahoma by expanding Medicaid, legalizing marijuana (Dallas Morning News) 
Minnesota front-line workers could see $750 hero checks within 12 weeks (Duluth News Tribune)

THE HILL OPEDS

Was mask mandate judge a hypocrite? 
Air travel trends on the move

That’s it for today, thanks for reading. Check out The Hill’s Health Care page for the latest news and coverage. See you tomorrow.

VIEW THE FULL VERSION HERE.

Previous Post

FDA expands approval of non-stimulant ADHD drug to adults

Next Post

Planned Parenthood: Draft Supreme Court ruling striking down Roe v. Wade ‘devastating’

Next Post
Planned Parenthood: Draft Supreme Court ruling striking down Roe v. Wade ‘devastating’

Planned Parenthood: Draft Supreme Court ruling striking down Roe v. Wade 'devastating'

  • Trending
  • Comments
  • Latest
Vaccine protection against COVID-19 related issues

Vaccine protection against COVID-19 related issues

April 26, 2022
2 in 3 physicians concerned about AI driving diagnosis, treatment decisions: Survey

2 in 3 physicians concerned about AI driving diagnosis, treatment decisions: Survey

October 31, 2023
Religious services may lower risk of ‘deaths of despair’

Religious services may lower risk of ‘deaths of despair’

April 26, 2022
Signaling molecule may prevent Alzheimer’s

Signaling molecule may prevent Alzheimer’s

April 26, 2022
How long does it take weight loss drugs to work?

How long does it take weight loss drugs to work?

0
7 Tips to Make Your Workout Routine More Sustainable

7 Tips to Make Your Workout Routine More Sustainable

0
11 Weight Loss Tips That Will Get you Fast Results

11 Weight Loss Tips That Will Get you Fast Results

0
What are the Sunday Scaries? Plus, Here’s How to Beat Them

What are the Sunday Scaries? Plus, Here’s How to Beat Them

0
How long does it take weight loss drugs to work?

How long does it take weight loss drugs to work?

May 31, 2025
How long does it take weight loss drugs to work?

How long does it take weight loss drugs to work?

May 31, 2025
CDC adjusts COVID vaccine guidance, but keeps on child schedule

CDC adjusts COVID vaccine guidance, but keeps on child schedule

May 30, 2025
Kansas law nullifying end-of-life wishes during pregnancy challenged in court

Kansas law nullifying end-of-life wishes during pregnancy challenged in court

May 30, 2025

Recent News

How long does it take weight loss drugs to work?

How long does it take weight loss drugs to work?

May 31, 2025
How long does it take weight loss drugs to work?

How long does it take weight loss drugs to work?

May 31, 2025
CDC adjusts COVID vaccine guidance, but keeps on child schedule

CDC adjusts COVID vaccine guidance, but keeps on child schedule

May 30, 2025
Kansas law nullifying end-of-life wishes during pregnancy challenged in court

Kansas law nullifying end-of-life wishes during pregnancy challenged in court

May 30, 2025
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting
  • Contact Us
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Disclaimer: Healthyfemalearmy.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized beauty advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give health advice or provide beauty recommendation. Any recommendations here should be taken into consideration only after consulting with your doctor.
© 2025 Healthyfemalearmy.com. All rights reserved.

No Result
View All Result
  • Contact Us
  • Email Whitelisting
  • Home 1
  • Privacy Policy
  • Terms and Conditions
  • Terms and Conditions

Disclaimer: Healthyfemalearmy.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized beauty advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give health advice or provide beauty recommendation. Any recommendations here should be taken into consideration only after consulting with your doctor.
© 2025 Healthyfemalearmy.com. All rights reserved.